Literature DB >> 21382112

Cognitive enhancement in combination with 'brain repair' may be optimal for the treatment of stimulant addiction.

Jennifer M Loftis, Marilyn Huckans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21382112      PMCID： PMC4420025          DOI： 10.1111/j.1360-0443.2010.03354.x

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  19 in total

1.  Methamphetamine administration produces immunomodulation in mice.

Authors:  Sang-Whan In; Eun-Wha Son; Dong-Kwon Rhee; Suhkneung Pyo
Journal:  J Toxicol Environ Health A       Date:  2005-12-10

Review 2.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

3.  Neuropsychological function and delay discounting in methamphetamine-dependent individuals.

Authors:  William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

4.  Methamphetamine causes persistent immune dysregulation: a cross-species, translational report.

Authors:  Jennifer M Loftis; Dongseok Choi; William Hoffman; Marilyn S Huckans
Journal:  Neurotox Res       Date:  2010-10-17       Impact factor: 3.911

5.  A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.

Authors:  Bankole A Johnson; Nassima Ait-Daoud; Ahmed M Elkashef; Edwina V Smith; Roberta Kahn; Francis Vocci; Shou-Hua Li; Daniel A Bloch
Journal:  Int J Neuropsychopharmacol       Date:  2007-05-01       Impact factor: 5.176

6.  Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.

Authors:  Nora D Volkow; Joanna S Fowler; Jean Logan; David Alexoff; Wei Zhu; Frank Telang; Gene-Jack Wang; Millard Jayne; Jacob M Hooker; Christopher Wong; Barbara Hubbard; Pauline Carter; Donald Warner; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Karen Apelskog-Torres
Journal:  JAMA       Date:  2009-03-18       Impact factor: 56.272

7.  Methamphetamine causes microglial activation in the brains of human abusers.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Genichi Sugihara; Nori Takei; Etsuji Yoshikawa; Kazuhiko Nakamura; Yasuhide Iwata; Kenji J Tsuchiya; Shiro Suda; Katsuaki Suzuki; Masayoshi Kawai; Kiyokazu Takebayashi; Shigeyuki Yamamoto; Hideo Matsuzaki; Takatoshi Ueki; Norio Mori; Mark S Gold; Jean L Cadet
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

8.  Methamphetamine enhances histoplasmosis by immunosuppression of the host.

Authors:  Luis R Martinez; Mircea Radu Mihu; Attila Gácser; Laura Santambrogio; Joshua D Nosanchuk
Journal:  J Infect Dis       Date:  2009-07-01       Impact factor: 5.226

9.  Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.

Authors:  Steven Shoptaw; Keith G Heinzerling; Erin Rotheram-Fuller; Trevor Steward; Jason Wang; Aimee-Noelle Swanson; Richard De La Garza; Tom Newton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-05-12       Impact factor: 4.492

10.  Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers.

Authors:  Edythe D London; Sara L Simon; Steven M Berman; Mark A Mandelkern; Aaron M Lichtman; Jennifer Bramen; Ann K Shinn; Karen Miotto; Jennifer Learn; Yun Dong; John A Matochik; Varughese Kurian; Thomas Newton; Roger Woods; Richard Rawson; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2004-01
View more
  3 in total

Review 1.  Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.

Authors:  Jennifer M Loftis; Marilyn Huckans
Journal:  Pharmacol Ther       Date:  2013-04-28       Impact factor: 12.310

2.  Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction.

Authors:  Jennifer M Loftis; Clare J Wilhelm; Arthur A Vandenbark; Marilyn Huckans
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

3.  Plasma Inflammatory Factors Are Associated with Anxiety, Depression, and Cognitive Problems in Adults with and without Methamphetamine Dependence: An Exploratory Protein Array Study.

Authors:  Marilyn Huckans; Bret E Fuller; Alison L N Chalker; Madeleine Adams; Jennifer M Loftis
Journal:  Front Psychiatry       Date:  2015-12-18       Impact factor: 4.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.